Brainstorm Cell Therapeutics (Nasdaq:BCLI) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BCLI 주식 개요

생명공학 회사인 브레인스톰 셀 테라퓨틱스는 신경 퇴행성 질환 치료를 위한 자가 세포 치료제의 개발 및 상용화에 종사하는 기업입니다.

BCLI 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	1/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 99.1% 에서 거래

지난 5년 동안 수입이 매년 3.3% 증가했습니다.

위험 분석

마이너스 주주 지분

수익이 1백만 달러 미만인 경우 ( $0 )

cash runway 경력이 1년 미만입니다.

지난 1년 동안 주주가 크게 희석되었습니다.

+ 4 더 많은 위험

Brainstorm Cell Therapeutics Inc. 경쟁사

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Vincerx Pharma

NasdaqCM:VINC

US$11.7m

Eagle Pharmaceuticals

OTCPK:EGRX

US$11.7m

BioRestorative Therapies

NasdaqCM:BRTX

US$11.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Brainstorm Cell Therapeutics
과거 주가
현재 주가	US$2.25
52주 최고치	US$11.89
52주 최저치	US$1.96
베타	0.32
11개월 변경	-38.22%
3개월 변경 사항	-58.22%
1년 변경 사항	-15.73%
33년 변화	-95.13%
5년 변화	-95.88%
IPO 이후 변화	-55.56%

최근 뉴스 및 업데이트

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

주주 수익률

	BCLI	US Biotechs	US 마켓
7D	12.5%	0.6%	0.8%
1Y	-15.7%	27.4%	38.4%

수익률 대 산업: BCLI 지난 1년 동안 22.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BCLI 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BCLI's price volatile compared to industry and market?
BCLI volatility
BCLI Average Weekly Movement	13.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

안정적인 주가: BCLI 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BCLI 의 주간 변동성은 지난 1년 동안 22% 에서 16% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	29	Chaim Lebovits	www.brainstorm-cell.com

생명공학 회사인 브레인스톰 셀 테라퓨틱스는 신경 퇴행성 질환 치료를 위한 자가 세포 치료제의 개발 및 상용화에 종사하고 있습니다. 이 회사는 독점적인 세포 치료 플랫폼인 NurOwn을 통해 세포 배양 방법을 활용하여 자가 골수 유래 중간엽 줄기세포가 높은 수준의 신경 영양 인자를 분비하도록 유도하고, 신경 염증 및 신경 퇴행성 질환 과정을 조절하며, 신경 세포 생존을 촉진하고 신경 기능을 향상시킵니다. 근위축성 측삭 경화증 치료를 위한 임상 3상, 진행성 다발성 경화증 치료를 위한 임상 2상, 알츠하이머병 및 기타 신경 퇴행성 질환 치료를 위한 임상 2상을 완료한 뉴로온을 개발 중입니다.

Brainstorm Cell Therapeutics Inc. 기본 사항 요약

Brainstorm Cell Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BCLI 기본 통계
시가총액	US$11.96m
수익(TTM)	-US$12.75m
수익(TTM)	n/a

0.0x

P/S 비율

-0.9x

P/E 비율

BCLI 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BCLI 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$12.75m
수익	-US$12.75m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.40
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

BCLI 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BCLI 주식 개요

보상

위험 분석

Brainstorm Cell Therapeutics Inc. 경쟁사

NasdaqCM:VBLT

US$12.1m

NasdaqCM:VINC

US$11.7m

OTCPK:EGRX

US$11.7m

NasdaqCM:BRTX

US$11.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

Recent updates

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

New major risk - Revenue and earnings growth

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update

Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

New minor risk - Profitability

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Price target decreased to US$13.00

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

Price target increased to US$11.00

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

New 90-day low: US$4.21